Tascom타스컴

Tascom is a small KONEX-listed diagnostics maker with no financial statements in the data, and its shares are up sharply over three months but down over a year.

Tascom develops and sells SimplexTAS, a point-of-care blood and urine testing system that relies on disposable cartridges, with most revenue coming from overseas sales through distributors. The shares closed at ₩3,900 on 2026-10-23, giving a market value of about ₩22.6B. The data does not include any annual or trailing financial results, so the current profitability and financial position cannot be assessed from this pack.

What stands out

• Shares are up 50.6% over three months and 2.6% over one month, but down 9.3% over one year.
• The stock trades about 26% below its 52-week high of ₩5,280; the 52-week low is shown as ₩0, which looks like a data gap rather than a real price.
• No revenue, profit, or valuation multiples (P/E, P/B, EV/EBITDA) are available, so the company cannot be compared on earnings with peers.
• Recent filings are mostly procedural: a shareholders' meeting notice and record-date setting on 2026-10-12, IR events, and insider and 5%+ holding reports.
• No news headlines were included in the data, and foreign ownership is recorded at 0%.

What to watch

• The shareholders' meeting and its agenda, as set out in the October 2026 filings.
• Any filed financial statements that would show revenue, profit, and cash position, which are missing from this data.
• Insider and 5%+ holding reports, given the thin trading and the wide gap between the 52-week high and low.